HPC
FOLD

HM Payson & Co’s Amicus Therapeutics FOLD Stock Holding History

HM Payson & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-845
Closed -$8K – 1113
2021
Q1 		$8K Hold
845
– – ﹤0.01% 891
2020
Q4 		$20K Sell
845
-232
-22% -$4.75K ﹤0.01% 768
2020
Q3 		$15K Buy
+1,077
New +$15.7K ﹤0.01% 780

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HM Payson & Co's FOLD Position: Q2 2021 in Review

HM Payson & Co sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 845 shares — an estimated $8K sold.

HM Payson & Co first reported a position in FOLD in Q3 2020 and held it in 3 quarters. The position peaked at $20K in Q4 2020. 234 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • HM Payson & Co reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 845 Amicus Therapeutics shares in Q2 2021, an estimated $8K.
  • HM Payson & Co first reported a position in Amicus Therapeutics in Q3 2020 and held it in 3 quarters.
  • HM Payson & Co's Amicus Therapeutics position peaked at $20K in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.